ArticleCancer research2008
Genetic variants contributing to daunorubicin-induced cytotoxicity.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pooled it
- Trial
- Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients.BMC medical genomics · 2025Article
- Analysis ofInternational journal of molecular sciences · 2024Article
- Ru(II) photocages enable precise control over enzyme activity with red light.Nature communications · 2022Article
- Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.Genome medicine · 2021Article
- Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations.Human molecular genetics · 2021Article
- Association of Genetic Variants atFrontiers in cardiovascular medicine · 2020Article
- Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.Current oncology reports · 2018Review
- Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.The pharmacogenomics journal · 2017Article
- Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.Current cardiology reports · 2016Review
- Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.Current molecular medicine · 2014Article
- A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway nodes.Frontiers in genetics · 2014Article
- Genetic and epigenetic variants contributing to clofarabine cytotoxicity.Human molecular genetics · 2013Article
- ATHENA: a tool for meta-dimensional analysis applied to genotypes and gene expression data to predict HDL cholesterol levels.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2013Article
- Genetic architecture of microRNA expression: implications for the transcriptome and complex traits.American journal of human genetics · 2012Article
- An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.Human molecular genetics · 2012Article
- Integrating heterogeneous high-throughput data for meta-dimensional pharmacogenomics and disease-related studies.Pharmacogenomics · 2012Article
- Bioinformatic Resources of microRNA Sequences, Gene Targets, and Genetic Variation.Frontiers in genetics · 2012Article
- Liver expression quantitative trait loci: a foundation for pharmacogenomic research.Frontiers in genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Identifying heritable genetic variants responsible for chemotherapeutic toxicities has been challenging due in part to its multigenic nature. To date, there is a paucity of data on genetic variants associated with patients experiencing severe myelosuppression or cardiac toxicity following treatment with daunorubicin. We present a genome-wide model using International HapMap cell lines that integrate genotype and gene expression to identify genetic variants that contribute to daunorubicin-induced cytotoxicity. A cell growth inhibition assay was used to measure variations in the cytotoxicity of daunorubicin. Gene expression was determined using the Affymetrix GeneChip Human Exon 1.0ST Array. Using sequential analysis, we evaluated the associations between genotype and cytotoxicity, those significant genotypes with gene expression and correlated gene expression of the identified candidates with cytotoxicity. A total of 26, 9, and 18 genetic variants were identified to contribute to daunorubicin-induced cytotoxicity through their effect on 16, 9, and 36 gene expressions in the combined, Centre d' Etude du Polymorphisme Humain (CEPH), and Yoruban populations, respectively. Using 50 non-HapMap CEPH cell lines, single nucleotide polymorphisms generated through our model predicted 29% of the overall variation in daunorubicin sensitivity and the expression of CYP1B1 was significantly correlated with sensitivity to daunorubicin. In the CEPH validation set, rs120525235 and rs3750518 were significant predictors of transformed daunorubicin IC(50) (P = 0.005 and P = 0.0008, respectively), and rs1551315 trends toward significance (P = 0.089). This unbiased method can be used to elucidate genetic variants contributing to a wide range of cellular phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.